The purpose of this study is to characterize the effect of renal function on the plasma, urine, and dialysate pharmacokinetic profile of CB-238,618 in humans. The study will also assess the safety profile and tolerability of CB-238,618 in subjects with varying degrees of renal impairment and in healthy subjects.